Nuvation Bio Inc. Active Patents
8 granted patents the USPTO still lists as patented, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2023-09-22: Application 18472993; Invention ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS; Applicant Nuvation Bio Inc.; Status Patented Case.
- 2022-11-22: Application 18058220; Invention ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS; Applicant Nuvation Bio Inc.; Status Patented Case.
- 2022-05-02: Application 17735011; Invention ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS; Applicant Nuvation Bio Inc.; Status Patented Case.
- 2022-03-22: Application 17701425; Invention ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS; Applicant Nuvation Bio Inc.; Status Patented Case.
| Filed | Application | Invention | Applicant | Status | Granted | Patent | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-22 | 18472993 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. | Patented Case | 2025-01-28 | 12208141 | US20240181066A1 | David HUNG Son Minh PHAM Sarvajit CHAKRAVARTY Jiyun CHEN Jayakanth KANKANALA Jeremy D. PETTIGREW Anup BARDE Anjan Kumar NAYAK | United States United States United States United States United States Canada India India | RAHMANI, NILOOFAR |
| 2022-11-22 | 18058220 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. | Patented Case | 2025-08-26 | 12398121 | US20230122310A1 | David Hung Son Minh Pham Sarvajit Chakravarty Jiyun Chen Jayakanth Kankanala Anup Barde Anjan Kumar Nayak | United States United States United States United States United States India India | KIFLE, BRUCK |
| 2022-05-02 | 17735011 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. | Patented Case | 2024-06-11 | 12006314 | US20220380364A1 | David Hung Jayakanth Kankanala Christopher Paul Miller Jeremy David Pettigrew Son Minh Pham Ihab S. Darwish | United States United States United States Canada United States United States | SHIM, DAVID M. |
| 2022-03-22 | 17701425 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. | Patented Case | 2023-12-05 | 11834458 | US20220340587A1 | David Hung Jayakanth Kankanala Christopher Paul Miller Jeremy David Pettigrew Son Minh Pham Ihab S. Darwish | United States United States United States Canada United States United States | AULAKH, CHARANJIT |
| 2020-11-12 | 17096743 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. | Patented Case | 2024-04-09 | 11952349 | US20210214316A1 | Son Minh Pham Jayakanth Kankanala Jeremy Pettigrew Christopher Paul Miller | United States United States Canada United States | MURRAY, JEFFREY H |
| 2020-07-01 | 16918997 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC. | Patented Case | 2023-02-21 | 11584756 | US20210002293A1 | Son Minh PHAM Sarvajit CHAKRAVARTY Jayakanth KANKANALA Jiyun CHEN Chris P. MILLER Jeremy D. PETTIGREW Anjan Kumar NAYAK Anup BARDE | United States United States United States United States United States Canada India India | RAHMANI, NILOOFAR |
| 2020-05-13 | 15931495 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. | Patented Case | 2023-11-28 | 11826430 | US20200360523A1 | David Hung Son Minh Pham Sarvajit Chakravarty Jiyun Chen Jayakanth Kankanala Jeremy D. Pettigrew Anup Barde Anjan Kumar Nayak | United States United States United States United States United States Canada India India | RAHMANI, NILOOFAR |
| 2019-10-30 | 16669421 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | NUVATION BIO INC. | Patented Case | 2021-12-07 | 11192900 | US20200140459A1 | Son Minh PHAM Sarvajit CHAKRAVARTY Jayakanth KANKANALA Jiyun CHEN Anjan Kumar NAYAK Anup BARDE | United States United States United States United States India India | WILLIS, DOUGLAS M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |